

Cancer Conference Update: A Multimedia Review of Key Presentations from the 2016 American Society of Hematology Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following was demonstrated in the Phase III StaMINA trial evaluating transplant with RVD consolidation and lenalidomide maintenance versus tandem transplant and lenalidomide maintenance versus single transplant with lenalidomide maintenance as up-front treatment for multiple myeloma (MM)?
 - Comparable progression-free survival (PFS) and overall survival (OS) for the 3 arms
 - A survival advantage with the addition of consolidation and maintenance treatment
 - A survival advantage with tandem transplant
 - None of the above
- Which of the following has been observed regarding the gastrointestinal (GI) side effects associated with ixazomib?
 - GI side effects tend to occur later in the course of therapy as a cumulative effect of treatment
 - GI side effects tend to occur early during the first 3 weeks of treatment
 - GI side effects are rarely observed
- Which of the following has been observed with venetoclax in patients with relapsed/refractory MM?
 - An objective response rate of <5%
 - An objective response rate of >60%
 - An objective response rate of 40% in patients with translocation 11;14
- The addition of bortezomib to up-front treatment with melphalan/dexamethasone in patients with AL amyloidosis results in improved hematologic and organ responses, and it is proposed that this regimen be a new standard therapy in this setting.
 - True
 - False
- Which of the following was observed in the Phase III GALLIUM study evaluating obinutuzumab- versus rituximab-based induction and maintenance therapy in patients with previously untreated follicular lymphoma?
 - No difference in PFS
 - PFS favored rituximab
 - PFS favored obinutuzumab
- Which of the following was observed in the Phase III LyMa study evaluating rituximab maintenance versus watch and wait after autologous stem cell transplant in younger patients with mantle cell lymphoma?
 - Prolonged event-free survival
 - Prolonged PFS
 - Prolonged OS
 - All of the above
 - Both a and b
 - Both a and c
 - Both b and c
- Vadastuximab talirine is an _____.
 - Anti-CD30 monoclonal antibody under investigation in Hodgkin lymphoma
 - Anti-CD33 antibody-drug conjugate under investigation in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
 - Anti-CD22 antibody-drug conjugate under investigation in acute lymphoblastic leukemia and chronic myeloid leukemia

Cancer Conference Update: A Multimedia Review of Key Presentations from the 2016 American Society of Hematology Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

8. Which of the following was observed in a Phase III trial evaluating the addition of idelalisib to bendamustine/rituximab for patients with relapsed/refractory chronic lymphocytic leukemia?
- a. Improvement in OS with idelalisib
 - b. Increased number of opportunistic infections with idelalisib
 - c. The study was closed early because of idelalisib-associated severe toxicity
 - d. Both a and b
 - e. Both b and c
9. In a study presented by Dr Garcia-Manero and colleagues, approximately what percent of patients with MDS or AML that was refractory to prior hypomethylating agents (azacitidine or decitabine) responded to CC-486 (oral azacitidine)?
- a. Less than 10%
 - b. 20%
 - c. 40%
10. Mutations in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 occur in approximately 25% to 30% of patients with AML and represent actionable targets for treatment.
- a. True
 - b. False